For the quarter ended September 30, 2025, the Company reported a net loss applicable to common stockholders of $8.2 million, or ($0.13) per share, compared to a net loss applicable to common ...

Although treatment with direct acting antivirals reduced hepatic steatosis in patients with chronic hepatitis C and fatty ...

New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The ...

The retrospective phase 2b study, which explored the use of various non-invasive tests (NITs) to assess response to semaglutide, adds to growing evidence that the drug not only improves metabolic ...

Altimmune’s pemvidutide shows promising Phase IIb MASH results; see key benefits, risks, and a bullish outlook. Read here for ...

Routine liver function tests (LFTs) typically comprise alanine aminotransferase (ALT), alkaline phosphatase (ALP), bilirubin, ...

A newly developed tool, called the DILI-Inpt prognostic score, can predict patients with drug-induced liver injury who are ...

A newly developed tool, called the DILI-Inpt prognostic score, can predict patients with drug-induced liver injury who are ...

Resmetirom sustained improvements in liver stiffness and several liver biomarkers among patients with metabolic ...

According to DataM Intelligence, the NASH/MASH Treatment Market Size was valued at USD 7.87 billion in 2024 and is projected ...

FARMVILLE, Va. (AP) — Johan Nziemi scored 16 points as Longwood beat Division-III member Mary Baldwin 92-55 on Monday. Nziemi also had nine rebounds for the Lancers. Jacoi Hutchinson scored 15 points ...